Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer
NCT ID: NCT02758652
Last Updated: 2021-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
160 participants
OBSERVATIONAL
2016-05-31
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Objectives: To screen microRNAs from prospectively collected plasma, urine and tumor samples from patients diagnosed with epithelial ovarian cancer. Samples are analyzed for microRNA expression and differential expression is correlated with primary treatment response, progression-free survival and overall survival.
• Methods: Plasma, urine and tumor samples are collected at primary surgery (open surgery or diagnostic laparoscopy) or interval debulking surgery, at 1st, 3rd and 6th neoadjuvant or adjuvant chemotherapy and at progression for high-throughput screening of microRNA expression by array technology.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia
NCT04001023
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
NCT02728622
Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO
NCT06917469
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
NCT04752865
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
NCT05574673
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
patients operated for a suspected ovarian malignancy in the Department of Obstetrics and Gynecology in Tampere University Informed consent obtained
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University
OTHER
University of Helsinki
OTHER
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Annika Auranen
Chief in gynecological oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Annika Auranen, adj prof
Role: PRINCIPAL_INVESTIGATOR
Chief of Gynecological Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampere University Hospital
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Savolainen K, Scaravilli M, Ilvesmaki A, Staff S, Tolonen T, Maenpaa JU, Visakorpi T, Auranen A. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020 Jul 1;13(1):311. doi: 10.1186/s13104-020-05155-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R15134
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.